Pfizer to pay $2.26 billion for cancer treatment developer Trillium
Pfizer is spending more than $2 billion in cash to buy a drugmaker focused on cancer treatments.
Pfizer will pay $18.50 for each share of Trillium Therapeutics Inc., or more than double the stocks 60-day weighted average price.
Trillium has no products…
